EP3380452A4 - Ortsspezifische isotopische markierung von 1,4-dien-systemen - Google Patents

Ortsspezifische isotopische markierung von 1,4-dien-systemen Download PDF

Info

Publication number
EP3380452A4
EP3380452A4 EP16869026.1A EP16869026A EP3380452A4 EP 3380452 A4 EP3380452 A4 EP 3380452A4 EP 16869026 A EP16869026 A EP 16869026A EP 3380452 A4 EP3380452 A4 EP 3380452A4
Authority
EP
European Patent Office
Prior art keywords
site marking
specific isotopic
diene systems
diene
systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16869026.1A
Other languages
English (en)
French (fr)
Other versions
EP3380452A1 (de
EP3380452B1 (de
Inventor
Dragoslav VIDOVIC
Mikhail Sergeevich Shchepinov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Retrotope Inc
Original Assignee
Retrotope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrotope Inc filed Critical Retrotope Inc
Priority to EP21164404.2A priority Critical patent/EP3858843A1/de
Priority to EP21198459.6A priority patent/EP3950649A1/de
Publication of EP3380452A1 publication Critical patent/EP3380452A1/de
Publication of EP3380452A4 publication Critical patent/EP3380452A4/de
Application granted granted Critical
Publication of EP3380452B1 publication Critical patent/EP3380452B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C11/00—Aliphatic unsaturated hydrocarbons
    • C07C11/12—Alkadienes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C11/00—Aliphatic unsaturated hydrocarbons
    • C07C11/21—Alkatrienes; Alkatetraenes; Other alkapolyenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C407/00—Preparation of peroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C409/00—Peroxy compounds
    • C07C409/16—Peroxy compounds the —O—O— group being bound between two carbon atoms not further substituted by oxygen atoms, i.e. peroxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/822—Rhodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2523/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00
    • C07C2523/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals
    • C07C2523/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals of the platinum group metals
    • C07C2523/46—Ruthenium, rhodium, osmium or iridium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2531/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • C07C2531/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • C07C2531/22—Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2531/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • C07C2531/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • C07C2531/24—Phosphines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
EP16869026.1A 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen Active EP3380452B1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21164404.2A EP3858843A1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen
EP21198459.6A EP3950649A1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258993P 2015-11-23 2015-11-23
PCT/US2016/051119 WO2017091279A1 (en) 2015-11-23 2016-09-09 Site-specific isotopic labeling of 1, 4-diene systems

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP21164404.2A Division EP3858843A1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen
EP21198459.6A Division EP3950649A1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen

Publications (3)

Publication Number Publication Date
EP3380452A1 EP3380452A1 (de) 2018-10-03
EP3380452A4 true EP3380452A4 (de) 2019-05-15
EP3380452B1 EP3380452B1 (de) 2021-03-24

Family

ID=58763673

Family Applications (3)

Application Number Title Priority Date Filing Date
EP21198459.6A Pending EP3950649A1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen
EP21164404.2A Pending EP3858843A1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen
EP16869026.1A Active EP3380452B1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP21198459.6A Pending EP3950649A1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen
EP21164404.2A Pending EP3858843A1 (de) 2015-11-23 2016-09-09 Ortsspezifische isotopische markierung von 1,4-dien-systemen

Country Status (10)

Country Link
US (7) US10730821B2 (de)
EP (3) EP3950649A1 (de)
JP (2) JP7048976B2 (de)
KR (1) KR102643910B1 (de)
CN (2) CN113214084A (de)
AU (4) AU2016361227B2 (de)
CA (1) CA3005983A1 (de)
ES (1) ES2871130T3 (de)
IL (2) IL259516B (de)
WO (1) WO2017091279A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113214084A (zh) 2015-11-23 2021-08-06 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
MX2020010425A (es) * 2018-04-04 2021-03-09 Retrotope Inc Composicion isotopicamente modificada y sus usos terapeuticos.
WO2020102596A1 (en) * 2018-11-15 2020-05-22 Retrotope, Inc. Deuterated compounds, compositions, and uses
JP2023514711A (ja) * 2020-02-21 2023-04-07 レトロトップ、 インコーポレイテッド 多価不飽和脂肪酸及びその誘導体の同位体修飾方法
CN111454114B (zh) * 2020-05-11 2023-07-14 长沙贝塔医药科技有限公司 一种用13c2-香叶醇合成高纯度13c2-月桂烯的方法
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
CA3227139A1 (en) * 2021-07-22 2023-01-26 Biojiva Llc Methods for inhibiting the progression of oxidative retinal diseases
EP4201403A1 (de) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Verbindungen tirapazamin und quazinon zur verwendung bei der behandlung von gm2-gangliosidosen
US20250057799A1 (en) * 2021-12-21 2025-02-20 Biojiva Llc Anti-Inflammatory Methods with Compositions Comprising Site-Specific Isotopically-Modified Fatty Acids
WO2023220058A1 (en) 2022-05-09 2023-11-16 Retrotope, Inc. Therapeutic methods for treating als
CN115894143B (zh) * 2022-10-31 2024-05-28 宁波萃英化学技术有限公司 氘代芳香化合物钯催化的双配体无导向制备方法
CN117456313B (zh) * 2023-12-22 2024-03-22 中国科学院宁波材料技术与工程研究所 色调曲线估计网络的训练方法、估计、映射方法及系统

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520872A (en) 1967-03-24 1970-07-21 Upjohn Co Process for labelling purine and pyrimidine containing compounds
US4792620A (en) * 1983-10-14 1988-12-20 Bp Chemicals Limited Carbonylation catalysts
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
JPH0614512Y2 (ja) 1987-10-29 1994-04-13 シャープ株式会社 アンテナ端子板
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
JPH0291955A (ja) 1988-09-29 1990-03-30 Nec Kansai Ltd 半導体ペレットのマウント方法
AU620929B2 (en) 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
DE69025922T2 (de) 1989-11-30 1996-10-02 Croda Int Plc Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
JPH0481156A (ja) 1990-07-24 1992-03-13 Matsushita Electric Ind Co Ltd コードレステレホン
ES2033193B1 (es) 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
WO1993009772A1 (fr) 1991-11-14 1993-05-27 Sagami Chemical Research Center Medicament contre des maladies hepatiques
JPH05246938A (ja) * 1992-02-19 1993-09-24 Sagami Chem Res Center 重水素標識高級脂肪酸
PT759929E (pt) 1994-05-19 2001-01-31 Merck & Co Inc Oxidacao de esteroides tendo grupos alilicos
FR2721518B3 (fr) 1994-06-28 1996-04-12 Gattefosse Ets Sa Compositions cosmétiques, pharmaceutiques, diététiques, vétérinaires contenant de l'eau.
FR2722410B1 (fr) 1994-07-15 1996-10-04 Grinda Jean Robert Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
JPH08268885A (ja) 1995-03-30 1996-10-15 Oyo Seikagaku Kenkyusho 過酸化脂質増量抑制剤
US5578334A (en) 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
CN1114878A (zh) 1995-06-09 1996-01-17 郑州铁路局中心医院 一种防治心血管系统疾病的制剂
JPH0950274A (ja) 1995-08-07 1997-02-18 Kawai Musical Instr Mfg Co Ltd アップライトピアノのフレーム
JPH09143492A (ja) 1995-11-17 1997-06-03 Katsumasa Koike 酸化脂質の確認方法及び酸化脂質の生成方法
JPH10291955A (ja) 1997-04-22 1998-11-04 Sagami Chem Res Center １３ｃ標識ドコサヘキサエン酸及びその製造方法
JPH1070439A (ja) 1996-08-29 1998-03-10 Hitachi Ltd 受信装置
US20030013772A1 (en) 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
JP4261049B2 (ja) 1997-10-08 2009-04-30 アイソテクニカ インコーポレイテッド 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用
US6270974B1 (en) 1998-03-13 2001-08-07 Promega Corporation Exogenous nucleic acid detection
EP1075286A2 (de) 1998-05-06 2001-02-14 Isotechnika, Inc. 13c glukose-atemtest zur diagnosis von diabetes
ATE361066T1 (de) 1998-10-15 2007-05-15 Dsm Ip Assets Bv Polyungesättigen fettsäuren nährungsergänzung
IT1304406B1 (it) 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US6503478B2 (en) 1999-01-13 2003-01-07 Lightouch Medical, Inc. Chemically specific imaging of tissue
US7271315B2 (en) 1999-01-14 2007-09-18 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
JP2000290291A (ja) 1999-03-31 2000-10-17 Nippon Sanso Corp 安定同位体標識オリゴヌクレオチド及びオリゴヌクレオチド検出方法
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
JP3432778B2 (ja) 1999-11-19 2003-08-04 森澤 紳勝 活性酸素消去剤の濃縮液、その製造方法および活性酸素消去剤パウダー
GB9929897D0 (en) 1999-12-18 2000-02-09 Slabas Antoni R Improvements in or relating to conjugated fatty acids and related compounds
JP2001270832A (ja) 2000-03-27 2001-10-02 Ito En Ltd 網膜障害予防剤
GB2368339B (en) 2000-10-26 2002-09-18 Yissum Res Dev Co Complex incorporating a plurality of antioxidants
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
JP2004531568A (ja) 2001-05-30 2004-10-14 ラクスデイル リミテッド 補酵素ｑおよびエイコサペンタエン酸（ｅｐａ）
GB0113348D0 (en) 2001-06-01 2001-07-25 Mars Uk Ltd Skin diet
US20030091553A1 (en) 2001-10-19 2003-05-15 Gehlsen Kurt R. Use of histamine to treat liver disease
US6870077B2 (en) 2002-01-30 2005-03-22 Edward O. Kenaschuk High linolenic acid flax
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
JP2004081156A (ja) 2002-08-28 2004-03-18 Shigeo Ota 糖尿病および糖尿病関連疾患の予測のためのマーカーおよび個体分類方法
AU2003268693A1 (en) 2002-09-30 2004-04-19 Ajinomoto Co., Inc. Method of producing stable isotope-labeled protein
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
JP2006510669A (ja) 2002-12-06 2006-03-30 アルコン，インコーポレイテッド 眼障害および眼疾患の処置のためのスーパーオキシドジスムターゼ模倣物
TW200413274A (en) 2002-12-27 2004-08-01 Wako Pure Chem Ind Ltd Deuteration or tritiation method
KR20050029582A (ko) 2003-09-23 2005-03-28 주식회사 리포젠 알지닌 공액리놀레인산 복합체를 포함하는 항산화 조성물
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP2007524674A (ja) 2004-01-19 2007-08-30 マーテック・バイオサイエンシーズ・コーポレーション リーリン欠損症または機能障害およびそれに関連する方法
US20050164908A1 (en) 2004-01-23 2005-07-28 Ginsberg Myron D. Neuroprotective complex for treatment of cerebral ischemia and injury
EP1841460A2 (de) 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutische formulierungen zur behandlung von beta-amyloid-bedingten erkrankungen
WO2006016357A1 (en) 2004-08-09 2006-02-16 Enzymotec Ltd. Food products for diabetics
JP2006053100A (ja) 2004-08-13 2006-02-23 Institute Of Physical & Chemical Research 動物の代謝解析方法、ラベル動物の製造方法、ラベル動物、および、動物のｎｍｒ測定方法
WO2006055965A2 (en) 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP1834639B8 (de) 2005-01-04 2016-12-07 Mochida Pharmaceutical Co., Ltd. Gegenmittel gegen die toxizität von fetten
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070004639A1 (en) 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
JP2009502745A (ja) 2005-07-08 2009-01-29 マーテック バイオサイエンシーズ コーポレーション 認知症および前認知症に関連した状態を治療するための多価不飽和脂肪酸
US20090306015A1 (en) 2005-12-20 2009-12-10 Silamed, Inc. Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds
US20070265340A1 (en) 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
AU2007204991A1 (en) 2006-01-05 2007-07-19 Kinemed, Inc. Compositions and methods of treatment using modulators of motonueron diseases
JP5137168B2 (ja) 2006-02-27 2013-02-06 独立行政法人科学技術振興機構 安定同位体標識脂肪族アミノ酸、その標的蛋白質への組み込み方法並びに蛋白質のｎｍｒ構造解析方法
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
US20100048705A1 (en) 2006-11-09 2010-02-25 Children's Medical Center Corporation Methods of treating and preventing neovascularization with omega-3 polyunsaturated fatty acids
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP1961311A1 (de) 2007-02-23 2008-08-27 Belovo S.A., Egg Science & Technology Nahrungsmittel, enthaltend mehrfach ungesättigte Fettsäuren, zur Vorbeugung chronischer Erkrankungen
JP2010521493A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． （６ｒ）−４，５，６，７−テトラヒドロ−ｎ６−プロピル−２，６−ベンゾチアゾール−ジアミンの放出調節製剤およびそれらの使用方法
US20080234197A1 (en) 2007-03-19 2008-09-25 Undurti N Das Method(s) of stabilizing and potentiating the actions and administration of brain-derived neurotrophic factor (BDNF)
KR20100016140A (ko) 2007-05-25 2010-02-12 산텐 세이야꾸 가부시키가이샤 가령 황반 변성의 예방 또는 치료제
WO2009015360A2 (en) 2007-07-26 2009-01-29 San Diego State University Research Foundation Catalysts for alkene isomerization and conjugating double bonds in polyunsaturated fats and oils
PL2182981T3 (pl) 2007-08-02 2013-06-28 Gilead Biologics Inc Sposoby i kompozycje do leczenia i diagnozowania zwłóknienia
US20090069354A1 (en) 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched gemcitabine
US20100267828A1 (en) 2007-10-31 2010-10-21 Anne Kristin Holmeide dha derivatives and their use as medicaments
US8021874B2 (en) 2008-01-28 2011-09-20 The Board Of Regents Of The University Of Oklahoma Very long chain polyunsaturated fatty acids, methods of production, and uses
EP2276774B1 (de) 2008-03-14 2016-08-17 Retrotope, Inc. Die genommethylierung modulierende therapeutische substanzen
US10029956B2 (en) 2008-03-14 2018-07-24 Retrotope, Inc. Therapies for cancer using isotopically substituted lysine
EP2110027A1 (de) 2008-04-01 2009-10-21 Nestec S.A. Langkettige mehrfach ungesättigte Fettsäuren (LC-PUFA) in Mutternahrung während der Schwangerschaft und Stillzeit
US8461348B2 (en) 2008-04-04 2013-06-11 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
CA2729053A1 (en) 2008-05-01 2009-11-05 Bruce A. Freeman Vinyl substituted fatty acids
JPWO2009151125A1 (ja) 2008-06-13 2011-11-17 持田製薬株式会社 肝障害の診断及び治療
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
EP2328572B1 (de) 2008-07-28 2018-06-13 Blanchette Rockefeller Neurosciences, Institute Pkc-aktivierende verbindungen zur behandlung von neurodegenerativen erkrankungen
BRPI0922871A2 (pt) 2008-12-11 2016-11-16 Biovista Inc metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
US20120046363A1 (en) 2009-05-11 2012-02-23 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
EP2440201A1 (de) 2009-06-10 2012-04-18 Energy4life Ag Verfahren und zusammensetzungen zur behandlung von insulinresistenz, diabetes mellitus typ 2, stoffwechselsyndrom und verwandten erkrankungen
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
WO2011053870A1 (en) * 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
WO2011097273A1 (en) 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
WO2012067111A1 (ja) 2010-11-16 2012-05-24 株式会社西崎創薬研究所 ＰＫＣ－ε活性化剤
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
EP2701695B1 (de) 2011-04-26 2019-04-03 Retrotope, Inc. Neurodegenerative erkrankungen und muskelerkrankungen mit polyungesättigten fettsäuren
JP6106158B2 (ja) 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 酸化的網膜疾患
KR102014526B1 (ko) * 2011-04-26 2019-08-26 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
WO2012174262A2 (en) 2011-06-14 2012-12-20 Cenestra Llc Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations
ES2889874T3 (es) 2014-03-13 2022-01-14 Retrotope Inc Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas
WO2015162265A1 (en) * 2014-04-24 2015-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) New lipophenol compounds and uses thereof
CN113214084A (zh) 2015-11-23 2021-08-06 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
CN107569684B (zh) 2016-07-05 2021-04-09 杰尼视界公司 生发配方
JP2023514711A (ja) 2020-02-21 2023-04-07 レトロトップ、 インコーポレイテッド 多価不飽和脂肪酸及びその誘導体の同位体修飾方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CYRIL JACQUOT ET AL: "Isotope Sensitive Branching and Kinetic Isotope Effects in the Reaction of Deuterated Arachidonic Acids with Human 12- and 15-Lipoxygenases +", BIOCHEMISTRY, vol. 47, no. 27, 1 July 2008 (2008-07-01), pages 7295 - 7303, XP055063133, ISSN: 0006-2960, DOI: 10.1021/bi800308q *

Also Published As

Publication number Publication date
US20190084913A1 (en) 2019-03-21
CN113214084A (zh) 2021-08-06
CN108698987B (zh) 2021-07-13
AU2021225202B2 (en) 2023-04-13
WO2017091279A1 (en) 2017-06-01
US20180339958A1 (en) 2018-11-29
US20210387938A1 (en) 2021-12-16
JP7048976B2 (ja) 2022-04-06
JP7355801B2 (ja) 2023-10-03
AU2021225202A1 (en) 2021-09-30
EP3380452A1 (de) 2018-10-03
US12060324B2 (en) 2024-08-13
EP3950649A1 (de) 2022-02-09
EP3380452B1 (de) 2021-03-24
IL259516A (en) 2018-07-31
CN108698987A (zh) 2018-10-23
IL285758A (en) 2021-09-30
AU2016361227B2 (en) 2021-06-10
US10730821B2 (en) 2020-08-04
US10577304B2 (en) 2020-03-03
US20210331998A1 (en) 2021-10-28
EP3858843A1 (de) 2021-08-04
AU2023204024A1 (en) 2023-07-13
JP2019501135A (ja) 2019-01-17
ES2871130T3 (es) 2021-10-28
KR20180091020A (ko) 2018-08-14
US20200109103A1 (en) 2020-04-09
IL285758B (en) 2022-05-01
CA3005983A1 (en) 2017-06-01
AU2016361227A1 (en) 2018-06-21
IL259516B (en) 2021-09-30
KR102643910B1 (ko) 2024-03-06
US11453637B2 (en) 2022-09-27
US20250223253A1 (en) 2025-07-10
US11447441B2 (en) 2022-09-20
AU2025202677A1 (en) 2025-05-08
US20240018085A1 (en) 2024-01-18
JP2022046501A (ja) 2022-03-23
AU2023204024B2 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
EP3380452A4 (de) Ortsspezifische isotopische markierung von 1,4-dien-systemen
EP3528716C0 (de) Osteotomiesysteme
EP3443001A4 (de) Regulierte bioschaltkreissysteme
EP3351718A4 (de) Belüftungsreiniger
EP3388133A4 (de) Entnebelungsvorrichtung
EP3360320C0 (de) Projektionssysteme und -verfahren
EP4311502C0 (de) Knochenpositionierungs- und -vorbereitungsführungssysteme
HUE059623T2 (hu) Páraképzõ rendszer
EP3324863C0 (de) Embolektomiesystem
HUE056517T2 (hu) Kompozit mûtrágya rendszerek
EP3592914C0 (de) Gebäudesystem
EP3394754A4 (de) Zeitplanung von hochparallelen anwendungen
EP3362614A4 (de) Deckensystem
FI12628U1 (fi) Tavaranvälitysjärjestelmä
EP3388693A4 (de) Klemme
EP3724406C0 (de) Bausystem
DK3336369T3 (da) Fastgørelsesanlæg
EP3654167A4 (de) Betriebssystemanlage
EP3655116C0 (de) Sprinkleranlage
EP3443928C0 (de) Chirurgisches system
EP3475069C0 (de) Pultrusionssystem
EP3359994A4 (de) Selbstantriebssystem
FI11301U1 (fi) Turvajärjestelmä
EP3341929C0 (de) Anzeigesysteme
LT3283706T (lt) Fasado elementų tvirtinimo konsolė

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602016055009

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07C0317040000

Ipc: C07B0059000000

A4 Supplementary search report drawn up and despatched

Effective date: 20190412

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 381/00 20060101ALI20190408BHEP

Ipc: C07C 69/67 20060101ALI20190408BHEP

Ipc: C07C 5/00 20060101ALI20190408BHEP

Ipc: C07C 29/00 20060101ALI20190408BHEP

Ipc: C07C 51/347 20060101ALI20190408BHEP

Ipc: C07C 407/00 20060101ALI20190408BHEP

Ipc: C07B 59/00 20060101AFI20190408BHEP

Ipc: C07C 67/30 20060101ALI20190408BHEP

Ipc: C07C 317/04 20060101ALI20190408BHEP

Ipc: C07C 11/12 20060101ALI20190408BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261107

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200225

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201013

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016055009

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 1374354

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210415

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210624

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210624

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210625

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1374354

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210324

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2871130

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210724

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210726

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016055009

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

26N No opposition filed

Effective date: 20220104

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210724

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210909

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210909

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210930

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250929

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250926

Year of fee payment: 10

Ref country code: IT

Payment date: 20250919

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250929

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250925

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210324

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251001

Year of fee payment: 10